NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.

The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.